Genetic testing changes for Pharmaceutical Benefits Scheme (PBS) immunotherapy

This page provides information about the 1 November 2022 changes to MBS pathology items 73337, 73341 and 73344

Page last updated: 28 October 2022

From 1 November 2022, pathology MBS items 73337, 73341 and 73344 will be amended to replace the reference to the specific drug ‘pembrolizumab’ with a general reference to ‘immunotherapy’.

The Medical Services Advisory Committee (MSAC) supported amendments to MBS items 73337, 73341 and 73344 to enable Medicare benefits to be payable for biomarker testing to determine if the PBS requirements for cemiplimab relating to EGFR, ALK or ROS1 gene status are met.

Further information is available in the following factsheet:

PDF Version Factsheet for changes to pathology MBS items 73337, 73341 and 73344 (PDF 154 KB)

Word Version Factsheet for changes to pathology MBS items 73337, 73341 and 73344 (Word 112 KB)

In this section